Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nolgileucel
- Development stage
- Phase 2
- Lead developer
- Shanghai Juncell Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Nolgileucel (GC101 TIL) is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy developed by Juncell Therapeutics (Shanghai Junsai Biological Technology) for the treatment of solid tumors, including advanced melanoma and non-small cell lung cancer (NSCLC). Unlike conventional TIL therapies that require high-intensity lymphodepleting chemotherapy and high-dose interleukin-2 (IL-2) administration, nolgileucel utilizes a proprietary DeepTIL® cell expansion platform to cultivate highly active TIL cells that do not require IL-2 administration and only require a low-intensity preconditioning regimen. This significantly reduces treatment-related toxicities and hospitalization times. In clinical trials, nolgileucel has demonstrated significant improvements in progression-free survival and objective response rates in patients with advanced melanoma who have failed prior anti-PD-1 therapy.
- Other names
- Nuoji Lun SaiNuojilunsai
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on nolgileucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nolgileucel.